&nbsp;

ColonCancerFITInstructionsKOH-FR

New

Mar 2026

Document

ColonCancerFITInstructionsKOH

New

Mar 2026

Document

H-FIT_EndoscopistFAQs

New

Mar 2026

Document

H-FIT_EndoscopistFAQs-FR

New

Mar 2026

Document

H-FIT_HospitalCoverLetter

New

Mar 2026

Document

H-FIT_PrimaryCareCoverLetter

New

Mar 2026

Document

H-FIT_HospitalCoverLetter-FR

New

Mar 2026

Document

H-FIT_PrimaryCareCoverLetter-FR

New

Mar 2026

Document

H-FIT_EndoscopistsCoverLetter-FR

New

Mar 2026

Document

H-FIT_EndoscopistsCoverLetter

New

Mar 2026

Regimen

CRBPPEME+PEMB

Cancer Type:

Lung,

Non-Small Cell

Intent: Neoadjuvant

Funding:

New Drug Funding Program

Pembrolizumab - (Neo)adjuvant Therapy for Resectable Non-Small Cell Lung Cancer

, Collapse Show fewer tags

Drugs Used:

Quick Link(s):

Regimen Monograph, Patient Info Sheet

Updated

Mar 2026

Regimen

CRBPPEME+PEMB

Cancer Type:

Gastrointestinal,

Mesothelioma (Peritoneal),

Lung,

Mesothelioma (Pleural)

Intent: Palliative

Funding:

New Drug Funding Program

Pembrolizumab - Previously Untreated Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma